ArticleExperimental eye research2014
28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.
Article in Experimental eye research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Long-Term Corticosteroid-Induced Ocular Hypertension Model Produced by Topical Rinderon-A Ointment Application.Biology · 2026Article
- Rodent Models of Glaucoma: How Mice and Rats Can Help Human Vision Move Out of the Woods and Into the Light.Cells · 2025Review
- Degradable Hydrogel Microspheres for Drug Delivery: In Vitro Performance and Influence of E-Beam Sterilization.AAPS PharmSciTech · 2025Article
- Fabrication of Anti-glaucoma Nanofibers as Controlled-Release Inserts for Ophthalmic Delivery of Brimonidine Tartrate:Advanced pharmaceutical bulletin · 2024Article
- Sustained release of brimonidine from polydimethylsiloxane-coating silicone rubber implant to reduce intraocular pressure in glaucoma.Regenerative biomaterials · 2023Article
- Controlled Release of Mesenchymal Stem Cell-Conditioned Media from a Microsphere/Gel-Based Drug Delivery System for Wound Healing of Tympanic Membrane Perforations.Journal of tissue engineering and regenerative medicine · 2023Article
- A Robust Microbead Occlusion Model of Glaucoma for the Common Marmoset.Translational vision science & technology · 2022Article
- Stimulation of α7 nAChR leads to regeneration of damaged neurons in adult mammalian retinal disease models.Experimental eye research · 2021Article
- Cranberry extract-based formulations for preventing bacterial biofilms.Drug delivery and translational research · 2021Article
- Considerations for Polymers Used in Ocular Drug Delivery.Frontiers in medicine · 2021Review
- A lab-on-a-chip model of glaucoma.Brain and behavior · 2020Article
- Article
- Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems.Molecules (Basel, Switzerland) · 2019Review
- Ocular Drug Delivery: A Special Focus on the Thermosensitive Approach.Nanomaterials (Basel, Switzerland) · 2019Review
- Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2019Article
- Tuning of thermoresponsive pNIPAAm hydrogels for the topical retention of controlled release ocular therapeutics.Journal of materials chemistry. B · 2019Article
- Sustained Dorzolamide Release Prevents Axonal and Retinal Ganglion Cell Loss in a Rat Model of IOP-Glaucoma.Translational vision science & technology · 2018Article
- Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Advanced healthcare materials · 2017Review
- Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop.Scientific reports · 2017Article
- Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery.ACS biomaterials science & engineering · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Treatment of glaucoma by intraocular pressure (IOP) reduction is typically accomplished through the administration of eye drops, the difficult and frequent nature of which contributes to extremely low adherence rates. Poor adherence to topical treatment regimens in glaucoma patients can lead to irreversible vision loss and increased treatment costs. Currently there are no approved treatments for glaucoma that address the inherent inefficiencies in drug delivery and patient adherence. Brimonidine tartrate (BT), a common glaucoma medication, requires dosing every 8-12 h, with up to 97% of patients not taking it as prescribed. This study provides proof-of-principle testing of a controlled release BT formulation. BT was encapsulated in poly(lactic-co-glycolic) acid microspheres and drug release was quantified using UV-Vis spectroscopy. For in vivo studies, rabbits were randomized to receive a single subconjunctival injection of blank (no drug) or BT-loaded microspheres or twice daily topical 0.2% BT drops. The microspheres released an average of 2.1 ± 0.37 μg BT/mg microspheres/day in vitro. In vivo, the percent decrease in IOP from baseline was significantly greater in the treated eye for both topical drug and drug-loaded microspheres versus blank microspheres throughout the 4-week study, with no evidence of migration or foreign body response. IOP measurements in the contralateral, untreated eyes also suggested a highly localized effect from the experimental treatment. A treatment designed using the release systems described in this study would represent a vast improvement over the current clinical standard of 56-84 topical doses over 28 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.